Atea Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Atea Pharmaceuticals, Inc. (AVIR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 2.55 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 1.92M shares, a 738.05% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 621.81K shares, a 58.69% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 70.26K shares, a 170.94% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 691.76K shares, a 967.53% increase from fiscal 2024.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 64.80K shares, a 83.49% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 392.51K shares, a 36.05% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 613.74K shares, a 107.12% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.92M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 2.55M shares 10-Q · filed 2026-08-12 | 2.55M shares derived: sum of 3 quarters · filed 2026-08-12 | 2.62M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 621.81K shares 10-Q · filed 2026-05-12 | 621.81K shares derived: sum of 2 quarters · filed 2026-05-12 | 692.07K shares derived: sum of 3 quarters · filed 2026-05-12 | 921.73K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 70.26K shares derived: sum of 2 quarters · filed 2026-03-05 | 299.92K shares derived: sum of 3 quarters · filed 2026-03-05 | 691.76K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 70.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 299.92K shares derived: sum of 2 quarters · filed 2025-11-12 | 691.76K shares 10-Q · filed 2025-11-12 | 691.76K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 229.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 621.50K shares 10-Q · filed 2025-08-07 | 621.50K shares derived: sum of 3 quarters · filed 2025-08-07 | 647.43K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 391.84K shares 10-Q · filed 2025-05-12 | 391.84K shares derived: sum of 2 quarters · filed 2025-05-12 | 417.77K shares derived: sum of 3 quarters · filed 2025-05-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 25.93K shares derived: sum of 2 quarters · filed 2025-03-06 | 64.80K shares 10-K · filed 2025-03-06 | |
| 2024-09-30 | 25.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 64.80K shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 38.87K shares 10-Q · filed 2024-08-07 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 9.71K shares derived: sum of 2 quarters · filed 2024-02-28 | 109.36K shares derived: sum of 3 quarters · filed 2024-02-28 | 392.51K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 9.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 109.36K shares derived: sum of 2 quarters · filed 2023-11-08 | 392.51K shares 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 99.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 382.80K shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 283.15K shares 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | 613.74K shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 296.31K shares 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 288.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 588.96K shares 10-K · filed 2021-03-30 | ||
| 2020-09-30 | 300.00K shares 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |